Floatz logo

SEVIPROTIMUT-L

Sexual Dysfunction

Applied Biology, Inc.vaccineEarly Phase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Sexual Dysfunction cohort.

Asset / SponsorPhaseRating
Tadalafil
University of Roma La Sapienza
Phase 4BBB
TESTOSTERONE UNDECYLATE
Alliance for Clinical Trials in Oncology
Phase 3BB
Risperdal
Si Tianmei
Phase 4BB
CITALOPRAM
Si Tianmei
Phase 4BB
Paliperidone Palmitate 3-Month Formulation
Si Tianmei
Phase 4BB

View all 15 →

Same molecule, other indications

SEVIPROTIMUT-L is also rated in:

Relapsed or Refractory Hodgkin LymphomaDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
CC
Indicative ·
43 / 100
View asset →
Peripheral T Cell LymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →